logo

DMAC

Diamedica·NASDAQ
--
--(--)
--
--(--)

DMAC fundamentals

Diamedica (DMAC) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.17 (YoY -13.33%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.17
-13.33%
Report date
Nov 12, 2025
DMAC Earnings Call Summary for Q3,2025
  • Preeclampsia progress: DM199 shows dose-dependent BP drops (systolic/diastolic) and placental perfusion improvements, positioning for U.S. trial.
  • Stroke challenges: Enrollment halved due to AI referrals; 35+ sites activated, seeking global expansion.
  • Financial stability: $55.3M cash, net loss up 37% YoY driven by clinical costs.
  • Key milestones: Cohort 10 expansion, FDA pre-IND update, and ReMEDy2 interim analysis in H2 2026.
EPS
Revenue

Revenue & Expenses

Key Indicators

Diamedica (DMAC) key financial stats and ratios, covering profitability, financial health, and leverage.
Diamedica (DMAC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Diamedica (DMAC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Diamedica (DMAC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Diamedica (DMAC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Diamedica (DMAC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield